On August 15, 2024, Michael Landsittel, Chief Financial Officer of Blueprint Medicines Corp (NASDAQ:BPMC), sold 4,409 shares of the company’s stock. The transaction was documented in a recent SEC filing. Following this sale, the insider now owns 67,208 shares of the company’s stock. Blueprint Medicines Corp, based in Cambridge, Massachusetts, focuses on developing precision therapies […]